Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lanthanum carbonate (Shire).

Francesco Locatelli1, Marco D'Amico, Giuseppe Pontoriero

  • 1A Manzoni Hospital, Department of Nephrology and Dialysis, Via Dell'Eremo 9-11, 23900 Lecco (Lc), Italy. nefrologia@ospedale.lecco.it

Idrugs : the Investigational Drugs Journal
|July 16, 2003
PubMed
Summary

Shire Pharmaceuticals is developing lanthanum carbonate for hyperphosphatemia in dialysis patients. This phosphate binder is nearing approval in major markets and undergoing trials in Japan.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A meta-analysis of albuminuria as a surrogate endpoint for kidney failure.

Nature medicine·2025
Same author

A Case Report of Median Nerve Entrapment in a Supracondylar Humeral Fracture: Diagnosis, Treatment, and Results After 5 Years of Follow-Up.

Reports (MDPI)·2025
Same author

Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study.

Rheumatology (Oxford, England)·2025
Same author

Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression.

Clinical journal of the American Society of Nephrology : CJASN·2025

Area of Science:

  • Nephrology
  • Pharmacology

Background:

  • Hyperphosphatemia is a common complication in dialysis patients.
  • Effective phosphate binders are crucial for managing this condition.

Purpose of the Study:

  • To evaluate lanthanum carbonate as a novel phosphate binder.
  • To assess its potential in treating hyperphosphatemia in patients undergoing dialysis.

Main Methods:

  • Lanthanum carbonate, a lanthanum salt, is being developed.
  • Clinical trials are in progress across different geographical regions.

Main Results:

  • The drug is in pre-registration in the US, Canada, and Western Europe.
  • Early-stage clinical trials are underway in Japan.

Conclusions:

  • Lanthanum carbonate shows promise for managing hyperphosphatemia in dialysis patients.
  • Regulatory review and further clinical evaluation are ongoing.

Related Experiment Videos